[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337492-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337492-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","converging-and-evolving-immuno-genomic-routes-toward-immune-escape-in-breast-cancer","Converging and evolving immuno-genomic routes toward immune escape in breast cancer","","Tumor–immune interactions during breast cancer progression are not well understood. This study characterizes multiple sequential and parallel multi-region tumor and blood specimens from an index patient and a cohort of metastatic triple-negative breast cancers. It shows a continuous rise in tumor genomic heterogeneity and distinct molecular clocks linked to treatment resistance, enabling immune escape. TCR repertoire diversity declines over time via convergent evolution, while antigen presentation defects and reduced T-cell recruitment in metastases indicate an immune-avoidance microenvironment incompatible with effective antitumor responses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/converging-and-evolving-immuno-genomic-routes-toward-immune-escape-in-breast-cancer/337492/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/converging-and-evolving-immuno-genomic-routes-toward-immune-escape-in-breast-cancer/337492.png","ImageObject",300,407,{"name":42,"@type":43},"Anda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the study examine regarding breast cancer progression?","Question",{"text":63,"@type":64},"It investigates interactions between tumors and immune cells as breast cancer advances, focusing on how immune escape emerges over time.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are immune escape and treatment resistance connected in the results?",{"text":68,"@type":64},"The study finds that increasing tumor genomic heterogeneity and distinct molecular clocks correlate with resistance to treatment, eventually allowing tumors to escape immune control.",{"name":70,"@type":61,"acceptedAnswer":71},"What immune-related changes are observed over time in metastatic triple-negative breast cancer?",{"text":72,"@type":64},"The TCR repertoire loses diversity over time with convergent evolution, and metastases show antigen presentation defects alongside subdued T-cell recruitment, indicating an immune-avoidance microenvironment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337492,1790188555,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Article [https://doi.org/10.1038/s41467-024-45292-1](https://doi.org/10.1038/s41467-024-45292-1)  \nConverging and evolving immuno-genomic routes toward immune escape in  \nbreast cancer  \nReceived: 21 August 2023  \n\n| Accepted: 19 January 2024 |\n| --- |\n| |\n| Check for updates |\n\nJuan Blanco-Heredia 1,2,3,14, Carla Anjos Souza 1,2,14, Juan L. Trincado 4,5,14, Maria Gonzalez-Cao 6, Samuel Gonçalves-Ribeiro 7, Sara Ruiz Gil4,  \nDmytro Pravdyvets8, Samandhy Cedeño 1, Maurizio Callari 9, Antonio Marra3, Andrea M. Gazzo3, Britta Weigelt 3, Fresia Pareja 3, Theodore Vougiouklakis3, Achim A. Jungbluth3, Rafael Rosell 6, Christian Brander 1,10,11,  \nFrancesc Tresserra6, Jorge S. Reis-Filho 3, Daniel Guimarães Tiezzi 12,13,14, Nuria de la Iglesia 1, Holger Heyn 4,8 & Leticia De Mattos-Arruda 1,2   \nThe interactions between tumor and immune cells along the course of breast cancer progression remain largely unknown. Here, we extensively characterize multiple sequential and parallel multiregion tumor and blood specimens of an index patient and a cohort of metastatic triple-negative breast cancers. We demonstrate that a continuous increase in tumor genomic heterogeneity and distinct molecular clocks correlated with resistance to treatment, eventually allowing tumors to escape from immune control. TCR repertoire loses diversity over time, leading to convergent evolution as breast cancer progresses. Although mixed populations of effector memory and cytotoxic single T cells coexist in the peripheral blood, defects in the antigen presentation machinery coupled with subdued T cell recruitment into metastases are observed, indicating a potent immune avoidance microenvironment not compatible with an effective antitumor response in lethal metastatic disease. Our results demonstrate that the immune responses against cancer are not static, but rather follow dynamic processes that match cancer genomic progression, illustrating the complex nature of tumor and immune cell interactions.  \nBreast cancers are complex dynamic systems that arise in the context of spatially structured genomic and immune microenvironments1. The relative abundance of somatic mutations suggesting the presence of neoantigens capable of activating speciﬁc T cells is one of the key characteristics that make triple-negative breast cancer (TNBC) more likely to respond to immunotherapy than other breast cancer subtypes2.  \nPrevious studies have demonstrated that immunosuppressive interactions between tumor cells, surrounding stromal, and immune cells might support metastatic progression and escape from immune control, challenging the efﬁcacy of cancer immunotherapy3–5. Some of  \nthe major immune escape mechanisms that maximize the probability of a tumor to progress include loss of neoantigen presentation, immune cell exhaustion, and the presence of an immunosuppressive microenvironment6. At the genomic level, mutation rate, genomic instability, and pool size are the drivers of diversity, which may constitute driving forces imposed by immune pressures and consequently may lead to differential responses to therapies7–9. However, whether TNBC cancers diversify over time and across spatially distinct synchronous metastatic areas, evolving along a molecular clock into genomically diverse landscapes with distinct immune environments has yet to be understood.  \nA full list of afﬁliations appears at the end of the paper. e-mail: [ldmarruda@gmail.com](ldmarruda@gmail.com)  \nTo explore the sequential and parallel interplay between antitumor immunity and TNBC metastases, leading to immune escape, we extensively characterize a TNBC index patient leveraging single-cell peripheral blood T cell RNA and T cell receptor (TCR) sequencing, tumor bulk DNA, RNA and TCR sequencing, neoantigen T cell reactivity, clinical and immunohistologic data. We then extend the analyses to a series of eleven primary TNBCs and postmortem metastases previously published by our group and others10,11. Here, we identify the","cbCainVfYunUCeoY","https://ap.wps.com/l/cbCainVfYunUCeoY","pdf",3438919,18,"English","# Abstract\n## Study aims and overview\n## Results and key findings\n## Clinical and sample characteristics","[{\"question\":\"What does the study examine regarding breast cancer progression?\",\"answer\":\"It investigates interactions between tumors and immune cells as breast cancer advances, focusing on how immune escape emerges over time.\"},{\"question\":\"How are immune escape and treatment resistance connected in the results?\",\"answer\":\"The study finds that increasing tumor genomic heterogeneity and distinct molecular clocks correlate with resistance to treatment, eventually allowing tumors to escape immune control.\"},{\"question\":\"What immune-related changes are observed over time in metastatic triple-negative breast cancer?\",\"answer\":\"The TCR repertoire loses diversity over time with convergent evolution, and metastases show antigen presentation defects alongside subdued T-cell recruitment, indicating an immune-avoidance microenvironment.\"}]","Converging and evolving immuno-genomic routes toward immune escape in breast cancer | PDF",1790019330,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99e500f2c9d0b28344ad718bbaf3cbcc.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c1ee57ac723dc43797c45bb5cde5712.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e42d4fb35a7335cf02c906627bc538ff.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9fe87da95864352a70faa5e14dd1e5df.webp",980,1301]